02/05/2024 – 21:33
The pharmaceutical company Takeda, which produces the dengue vaccine (Qdenga), issued a statement this Monday (5) to inform the decision to prioritize meeting requests from the Ministry of Health in the supply of vaccines. According to the statement, Takeda has suspended the signing of direct contracts with states and municipalities and will limit the supply of the vaccine on the private network only to supply the amount necessary for people who have taken the first dose of the vaccine to complete the vaccination schedule with the second dose, after an interval of three months.
The measure was taken, according to the company, in light of the inclusion of Qdenga in the Unified Health System (SUS) and the worsening of the dengue epidemic in several regions of the country.
Related news:
“In line with the principle of equity in health, Takeda is committed to supporting health authorities, therefore its efforts are aimed at meeting the demand of the Ministry of Health, in accordance with the vaccination strategy defined by the Department of the National Immunization Program (DPNI ) that considers age range and regions to receive the vaccine. As already announced, we have guaranteed the delivery of 6.6 million doses for the year 2024 and the provision of a further 9 million doses for the year 2025. In parallel, we are seeking all possible solutions to increase the number of doses available in the country, and we will spare no effort to achieve this”, says the statement.
The decision does not affect commitments previously signed with municipalities before the incorporation of Qdenga into the SUS, the company noted.
Also according to the pharmaceutical company, the global supply of the Qdenga vaccine is expected to reach the target of 100 million doses per year by 2030, which includes a new international center dedicated to vaccine production, in Germany, scheduled to be launched in 2025. .
Vaccination
The Qdenga vaccine had its registration approved by the National Health Surveillance Agency (Anvisa) in March 2023. The process allows the product to be sold in Brazil, as long as the approved conditions are maintained. In December, the Ministry of Health announced the incorporation of the input into the Unified Health System (SUS).
Next week, doses will begin to be distributed to 521 municipalities selected by the Ministry of Health to begin vaccination in the public network. The cities make up a total of 37 health regions that, according to the ministry, are considered endemic for the disease. Children and adolescents aged 10 to 14 will be vaccinated, the age group that has the highest number of hospitalizations due to dengue, second only to the elderly.
>> Clear your doubts about the dengue vaccine
Epidemic
Brazil is experiencing an explosion of dengue cases that has caused the Federal District and three states, in addition to the city of Rio de Janeiro, to decree[https://agenciabrasil.ebc.com.br/saude/noticia/2024-02/dengue-faz-tres-estados-e-df-decretarem-situacao-de-emergencia” target=”_blank” rel=”noopener nofollow”> situação de emergência por conta da doença. Na última sexta-feira (3), o Ministério da Saúde abriu o Centro de Operações de Emergências (COE) contra a dengue, em Brasília.
#Manufacturer #give #priority #dengue #vaccine #SUS
